안과용 의약품 시장 규모, 점유율, 동향 분석 보고서 : 약물 종류별, 질환별, 제형별, 투여 경로별, 제품별, 약물 유형별, 지역별, 부문별 예측(2026-2033년)

Ophthalmic Drugs Market Summary

The global ophthalmic drugs market size was valued at USD 41.39 billion in 2025 and is projected to reach USD 79.44 billion by 2033, growing at a CAGR of 8.51% from 2026 to 2033. The market growth is attributed to the rising prevalence of eye disease, advancements in drug delivery, and an increasing focus on research for development of novel therapeutics in the market.

Eye diseases encompass a wide spectrum of morbidities that impact various components of the visual system and function. The increase in the prevalence of eye-related disorders, such as macular degeneration, diabetic retinopathy, and presbyopia, is one of the major factors driving the growth of the overall ophthalmic drug market. The increasing prevalence of these conditions is expected to boost the market. As per WHO, in 2023, approximately 2.2 billion people were visually impaired globally. Moreover, according to a study, "Global incidence and risk factors for glaucoma," published by the Journal of Global Health in November 2024, the worldwide incidence rate of Primary Open-Angle Glaucoma (POAG) in 2022 was 23.46 cases per 10,000 person-years for individuals aged 40 to 79. Between 1990 and 2019, there was a notable rise in this rate, increasing from 5.51 cases per 10,000 person-years in the 40 to 44 age group to 64.36 cases per 10,000 person-years in the 75 to 79 age group. This rising prevalence of eye conditions significantly increases the demand for effective ophthalmic drugs over the forecast period.

The growing geriatric population is anticipated to increase the number of people with eye conditions. According to the United Nations, the share of individuals aged 65 and older is growing more rapidly than that of younger populations. As a result, the percentage of the global population in this age group is anticipated to increase from 10% in 2022 to 16% by 2050. By that year, it is estimated that the number of people aged 65 and above will be twice that of children under the age of 5 and nearly equal to the number of children under 12. Presbyopia, cataracts, glaucoma, and AMD become more common as people get older. This growing adult population, coupled with the increasing prevalence of conditions such as diabetes, significantly increases the risk of various eye conditions, thereby contributing to market growth. According to the WHO, the population of individuals diagnosed with diabetes increased from 200 million in 1990 to 830 million by 2022. Some eye disorders, such as glaucoma, refractive error, and retinal degeneration, including retinitis pigmentosa, are also influenced by genetics. Another non-modifiable risk factor associated with an increased risk of acquiring some eye disorders is ethnicity.

Global Ophthalmic Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global ophthalmic drugs market report on the basis of drug class, disease, dosage form, route of administration, product, drug type, and region:

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• Anti-allergy
• Anti-inflammatory
  • Non-steroidal drugs
  • Steroids
• Anti-VEGF Agents
• Anti-glaucoma
• Others
• Disease Outlook (Revenue, USD Million, 2021 - 2033)
• Dry eye
  • Gels
  • Eye solutions & suspensions
  • Capsules & Tablets,
  • Eye drops
  • Ointments
• Allergies
  • Gels
  • Eye solutions & suspensions
  • Capsules & Tablets,
  • Eye drops
  • Ointments
• Glaucoma
  • Gels
  • Eye solutions & suspensions
  • Capsules & Tablets,
  • Eye drops
  • Ointments
• Infection
  • Gels
  • Eye solutions & suspensions
  • Capsules & Tablets,
  • Eye drops
  • Ointments
• Retinal Disorders
  • By Type
  • Macular Degeneration
  • Diabetic Retinopathy
  • Others
  • By Dosage Type
  • Gels
  • Eye solutions & suspensions
  • Capsules & Tablets,
  • Eye drops
  • Ointments
• Uveitis
  • Gels
  • Eye solutions & suspensions
  • Capsules & Tablets,
  • Eye drops
  • Ointments
• Others
  • Gels
  • Eye solutions & suspensions
  • Capsules & Tablets,
  • Eye drops
  • Ointments
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Topical
• Local Ocular
  • Subconjunctival
  • Intravitreal
  • Retrobulbar
  • Intracameral
• Systemic
• Dosage Form Outlook (Revenue, USD Million, 2021 - 2033)
• Gels
• Eye Solutions & Suspensions
• Capsules and Tablets
• Eye Drops
• Ointments
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Prescription Drugs
• OTC
• Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
• Branded Drugs
• Generic Drugs
• Regional Outlook (Revenue in USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug class
  • 1.2.2. Disease
  • 1.2.3. Route of administration
  • 1.2.4. Dosage Form
  • 1.2.5. Product
  • 1.2.6. Drug type
  • 1.2.7. Regional scope
  • 1.2.8. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug class outlook
  • 2.2.2. Disease outlook
  • 2.2.3. Route of administration outlook
  • 2.2.4. Dosage Form outlook
  • 2.2.5. Product outlook
  • 2.2.6. Drug type outlook
  • 2.2.7. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Ophthalmic Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing diseases prevalence
    • 3.2.1.2. String development pipeline
    • 3.2.1.3. Advancements in drug delivery
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Patent expiry of blockbuster drugs
• 3.3. Ophthalmic Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Ophthalmic Drugs Market: Drug Class Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Ophthalmic Drugs Market: Drug Class Movement Analysis
• 4.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
• 4.4. Anti-Allergy
  • 4.4.1. Anti-Allergy market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Anti-VEGF agents
  • 4.5.1. Anti-VEGF agents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Anti-inflammatory
  • 4.6.1. Anti-inflammatory market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Non-steroidal Drugs
    • 4.6.2.1. Non-steroidal Drugs market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Steroids
    • 4.6.3.1. Steroids market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Anti-glaucoma
  • 4.7.1. Anti-glaucoma market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Gene & Cell Therapy
  • 4.8.1. Gene & Cell Therapy market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Ophthalmic Drugs Market: Disease Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Ophthalmic Drugs Market: Disease Movement Analysis
• 5.3. Ophthalmic Drugs Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
• 5.4. Dry eye
  • 5.4.1. Dry eye market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.4.1.1. Gels
      • 5.4.1.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.4.1.2. Eye solutions & suspensions
      • 5.4.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.4.1.3. Capsules & tablets
      • 5.4.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.4.1.4. Eye drops
      • 5.4.1.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.4.1.5. Ointments
      • 5.4.1.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Allergies
  • 5.5.1. Allergies market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.5.1.1. Gels
      • 5.5.1.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.5.1.2. Eye solutions & suspensions
      • 5.5.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.5.1.3. Capsules & tablets
      • 5.5.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.5.1.4. Eye drops
      • 5.5.1.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.5.1.5. Ointments
      • 5.5.1.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Glaucoma
  • 5.6.1. Glaucoma market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.6.1.1. Gels
      • 5.6.1.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.6.1.2. Eye solutions & suspensions
      • 5.6.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.6.1.3. Capsules & tablets
      • 5.6.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.6.1.4. Eye drops
      • 5.6.1.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.6.1.5. Ointments
      • 5.6.1.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. Infection
  • 5.7.1. Infection market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.7.1.1. Gels
      • 5.7.1.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.7.1.2. Eye solutions & suspensions
      • 5.7.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.7.1.3. Capsules & tablets
      • 5.7.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.7.1.4. Eye drops
      • 5.7.1.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.7.1.5. Ointments
      • 5.7.1.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.8. Retinal Disorders
  • 5.8.1. Retinal disorders market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.8.2. By Dosage Type
    • 5.8.2.1. Gels
      • 5.8.2.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.8.2.2. Eye solutions & suspensions
      • 5.8.2.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.8.2.3. Capsules & tablets
      • 5.8.2.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.8.2.4. Eye drops
      • 5.8.2.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.8.2.5. Ointments
      • 5.8.2.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.8.3. By Type
    • 5.8.3.1. Macular degeneration
      • 5.8.3.1.1. Macular degeneration market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.8.3.2. Diabetic retinopathy
      • 5.8.3.2.1. Diabetic retinopathy market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.8.3.3. Others
      • 5.8.3.3.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.9. Uveitis
  • 5.9.1. Uveitis market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.9.1.1. Gels
      • 5.9.1.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.9.1.2. Eye solutions & suspensions
      • 5.9.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.9.1.3. Capsules & tablets
      • 5.9.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.9.1.4. Eye drops
      • 5.9.1.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.9.1.5. Ointments
      • 5.9.1.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.10. Others
  • 5.10.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.10.1.1. Gels
      • 5.10.1.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.10.1.2. Eye solutions & suspensions
      • 5.10.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.10.1.3. Capsules & tablets
      • 5.10.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.10.1.4. Eye drops
      • 5.10.1.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.10.1.5. Ointments
      • 5.10.1.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Ophthalmic Drugs Market: Route of Administration Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Ophthalmic Drugs Market: Route of Administration Movement Analysis
• 6.3. Ophthalmic Drugs Market Size & Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
• 6.4. Topical
  • 6.4.1. Topical market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Local Ocular
  • 6.5.1. Local ocular market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.1.1. Subconjunctival
      • 6.5.1.1.1. Subconjunctival market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.1.2. Intravitreal
      • 6.5.1.2.1. Intravitreal market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.1.3. Retrobulbar
      • 6.5.1.3.1. Retrobulbar market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.1.4. Intracameral
      • 6.5.1.4.1. Intracameral market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Sytemic
  • 6.6.1. Sytemic market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Ophthalmic Drugs Market: Dosage Form Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Ophthalmic Drugs Market: Dosage Form Movement Analysis
• 7.3. Ophthalmic Drugs Market Size & Trend Analysis, by Dosage Form, 2021 to 2033 (USD Million)
• 7.4. Gels
  • 7.4.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Eye solutions & suspensions
  • 7.5.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Capsules & Tablets
  • 7.6.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Eye drops
  • 7.7.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 7.8. Ointments
  • 7.8.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Ophthalmic Drugs Market: Product Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Ophthalmic Drugs Market: Product Movement Analysis
• 8.3. Ophthalmic Drugs Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 8.4. OTC
  • 8.4.1. OTC market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 8.5. Prescription Drugs
  • 8.5.1. Prescription drugs market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Ophthalmic Drugs Market: Drug Type Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Ophthalmic Drugs Market: Drug Type Movement Analysis
• 9.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
• 9.4. Branded Drugs
  • 9.4.1. Branded drugs market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 9.5. Generic Drugs
  • 9.5.1. Generic drugs market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 10. Ophthalmic Drugs Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Share Analysis, 2025 & 2033
• 10.2. Regional Market Dashboard
• 10.3. Global Regional Market Snapshot
• 10.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 10.5. North America
  • 10.5.1. U.S.
    • 10.5.1.1. Key country dynamics
    • 10.5.1.2. Regulatory framework/Reimbursement
    • 10.5.1.3. Competitive scenario
    • 10.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.5.2. Canada
    • 10.5.2.1. Key country dynamics
    • 10.5.2.2. Regulatory framework/Reimbursement
    • 10.5.2.3. Competitive scenario
    • 10.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.5.3. Mexico
    • 10.5.3.1. Key country dynamics
    • 10.5.3.2. Regulatory framework/Reimbursement
    • 10.5.3.3. Competitive scenario
    • 10.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 10.6. Europe
  • 10.6.1. UK
    • 10.6.1.1. Key country dynamics
    • 10.6.1.2. Regulatory framework/Reimbursement
    • 10.6.1.3. Competitive scenario
    • 10.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6.2. Germany
    • 10.6.2.1. Key country dynamics
    • 10.6.2.2. Regulatory framework/Reimbursement
    • 10.6.2.3. Competitive scenario
    • 10.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6.3. France
    • 10.6.3.1. Key country dynamics
    • 10.6.3.2. Regulatory framework/Reimbursement
    • 10.6.3.3. Competitive scenario
    • 10.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6.4. Italy
    • 10.6.4.1. Key country dynamics
    • 10.6.4.2. Regulatory framework/Reimbursement
    • 10.6.4.3. Competitive scenario
    • 10.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6.5. Spain
    • 10.6.5.1. Key country dynamics
    • 10.6.5.2. Regulatory framework/Reimbursement
    • 10.6.5.3. Competitive scenario
    • 10.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6.6. Norway
    • 10.6.6.1. Key country dynamics
    • 10.6.6.2. Regulatory framework/Reimbursement
    • 10.6.6.3. Competitive scenario
    • 10.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6.7. Sweden
    • 10.6.7.1. Key country dynamics
    • 10.6.7.2. Regulatory framework/Reimbursement
    • 10.6.7.3. Competitive scenario
    • 10.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6.8. Denmark
    • 10.6.8.1. Key country dynamics
    • 10.6.8.2. Regulatory framework/Reimbursement
    • 10.6.8.3. Competitive scenario
    • 10.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 10.7. Asia Pacific
  • 10.7.1. Japan
    • 10.7.1.1. Key country dynamics
    • 10.7.1.2. Regulatory framework/Reimbursement
    • 10.7.1.3. Competitive scenario
    • 10.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.7.2. China
    • 10.7.2.1. Key country dynamics
    • 10.7.2.2. Regulatory framework/Reimbursement
    • 10.7.2.3. Competitive scenario
    • 10.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.7.3. India
    • 10.7.3.1. Key country dynamics
    • 10.7.3.2. Regulatory framework/Reimbursement
    • 10.7.3.3. Competitive scenario
    • 10.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.7.4. Australia
    • 10.7.4.1. Key country dynamics
    • 10.7.4.2. Regulatory framework/Reimbursement
    • 10.7.4.3. Competitive scenario
    • 10.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.7.5. South Korea
    • 10.7.5.1. Key country dynamics
    • 10.7.5.2. Regulatory framework/Reimbursement
    • 10.7.5.3. Competitive scenario
    • 10.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.7.6. Thailand
    • 10.7.6.1. Key country dynamics
    • 10.7.6.2. Regulatory framework/Reimbursement
    • 10.7.6.3. Competitive scenario
    • 10.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 10.8. Latin America
  • 10.8.1. Brazil
    • 10.8.1.1. Key country dynamics
    • 10.8.1.2. Regulatory framework/Reimbursement
    • 10.8.1.3. Competitive scenario
    • 10.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.8.2. Argentina
    • 10.8.2.1. Key country dynamics
    • 10.8.2.2. Regulatory framework/Reimbursement
    • 10.8.2.3. Competitive scenario
    • 10.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 10.9. Middle East and Africa
  • 10.9.1. South Africa
    • 10.9.1.1. Key country dynamics
    • 10.9.1.2. Regulatory framework/Reimbursement
    • 10.9.1.3. Competitive scenario
    • 10.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.9.2. Saudi Arabia
    • 10.9.2.1. Key country dynamics
    • 10.9.2.2. Regulatory framework/Reimbursement
    • 10.9.2.3. Competitive scenario
    • 10.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.9.3. UAE
    • 10.9.3.1. Key country dynamics
    • 10.9.3.2. Regulatory framework/Reimbursement
    • 10.9.3.3. Competitive scenario
    • 10.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.9.4. Kuwait
    • 10.9.4.1. Key country dynamics
    • 10.9.4.2. Regulatory framework
    • 10.9.4.3. Competitive scenario
    • 10.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Recent Developments & Impact Analysis, By Key Market Participants
• 11.2. Company/Competition Categorization
• 11.3. Vendor Landscape
  • 11.3.1. List of key distributors and channel partners
  • 11.3.2. Key customers
  • 11.3.3. Key company market share analysis, 2023
  • 11.3.4. Alcon
    • 11.3.4.1. Company overview
    • 11.3.4.2. Financial performance
    • 11.3.4.3. Services benchmarking
    • 11.3.4.4. Strategic initiatives
  • 11.3.5. Novartis AG
    • 11.3.5.1. Company overview
    • 11.3.5.2. Financial performance
    • 11.3.5.3. Services benchmarking
    • 11.3.5.4. Strategic initiatives
  • 11.3.6. Bausch Health Companies, Inc.
    • 11.3.6.1. Company overview
    • 11.3.6.2. Financial performance
    • 11.3.6.3. Services benchmarking
    • 11.3.6.4. Strategic initiatives
  • 11.3.7. Merck & Co., Inc.
    • 11.3.7.1. Company overview
    • 11.3.7.2. Financial performance
    • 11.3.7.3. Services benchmarking
    • 11.3.7.4. Strategic initiatives
  • 11.3.8. Regeneron Pharmaceuticals, Inc.
    • 11.3.8.1. Company overview
    • 11.3.8.2. Financial performance
    • 11.3.8.3. Services benchmarking
    • 11.3.8.4. Strategic initiatives
  • 11.3.9. Coherus BioSciences, Inc.
    • 11.3.9.1. Company overview
    • 11.3.9.2. Financial performance
    • 11.3.9.3. Services benchmarking
    • 11.3.9.4. Strategic initiatives
  • 11.3.10. AbbVie, Inc. (Allergan)
    • 11.3.10.1. Company overview
    • 11.3.10.2. Financial performance
    • 11.3.10.3. Services benchmarking
    • 11.3.10.4. Strategic initiatives
  • 11.3.11. Pfizer, Inc.
    • 11.3.11.1. Company overview
    • 11.3.11.2. Financial performance
    • 11.3.11.3. Services benchmarking
    • 11.3.11.4. Strategic initiatives
  • 11.3.12. Bayer AG
    • 11.3.12.1. Company overview
    • 11.3.12.2. Financial performance
    • 11.3.12.3. Services benchmarking
    • 11.3.12.4. Strategic initiatives
  • 11.3.13. Santen Pharmaceutical Co., Ltd.
    • 11.3.13.1. Company overview
    • 11.3.13.2. Financial performance
    • 11.3.13.3. Services benchmarking
    • 11.3.13.4. Strategic initiatives
  • 11.3.14. Roche (Genentech, Inc.)
    • 11.3.14.1. Company overview
    • 11.3.14.2. Financial performance
    • 11.3.14.3. Services benchmarking
    • 11.3.14.4. Strategic initiatives
  • 11.3.15. Nicox
    • 11.3.15.1. Company overview
    • 11.3.15.2. Financial performance
    • 11.3.15.3. Services benchmarking
    • 11.3.15.4. Strategic initiatives